A Phase 3 interventional study of Human Albumin 20% Solution and Standard Care (in control arm) in Critical Illness and Septic Shock, sponsored by Mahidol University. Not yet recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Mahidol University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Shock, Septic by Mahidol University — 6 open to participants now, 6 under way, 1 of them phase 3. Shock, Septic · Mahidol University.
Among the 14 studies in Shock, Septic by Mahidol University, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 3, and was the 14th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →6 of the 14 studies in Shock, Septic by Mahidol University are open now, in 1 country. Recruiting first, the newest first:
Mahidol University · Sites in Thailand
Ages 18+
Mahidol University · Sites in Thailand
Ages 18+
Mahidol University · Sites in Thailand
Ages 18+
Mahidol University · Sites in Thailand
Ages 19–90
Mahidol University · Sites in Thailand
Ages 18+
By country, each count listing its studies:
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 304 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 145 across the 12 interventional studies, 490 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mahidol University is the lead sponsor of 750 studies on the registry; 123 are open to participants now.
2 of the studies in Shock, Septic by Mahidol University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07438301Mahidol UniversitySeptic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration | 2026-12-31 |
| NCT06937918Mahidol UniversityEffect of Dynamic Arterial Elastance and Assisted Fluid Management Software Guided Resuscitation in Septic Shock: Pilot Study | 2027-04-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Shock, Septic by Mahidol University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test whether giving human albumin to keep the blood albumin level above 3.5 g/dL, in addition to standard care, improves survival in patients with surgical septic shock. Septic shock is a life-threatening complication of infection that often requires urgent surgery and intensive care. Current treatment guidelines recommend intravenous fluids and medications to support blood pressure, but the best type of fluid is still uncertain.
Human albumin is a natural protein in the blood that helps maintain fluid balance and has anti-inflammatory effects. Previous studies suggest that low albumin levels are linked with worse outcomes in septic patients, and that albumin infusion might improve recovery, but results are mixed and evidence in surgical septic shock patients is lacking.
In this randomized controlled trial, adult patients with surgical septic shock admitted to the surgical intensive care unit will be randomly assigned to receive either standard care alone or standard care plus 20% human albumin solution for up to 3 days. The main outcome is survival at 28 days. Secondary outcomes include length of ICU and hospital stay, need for dialysis, ventilator-free days, vasopressor-free days, fluid balance, gastrointestinal recovery, and adverse reactions.
The results of this study will help determine whether targeted albumin replacement is beneficial in critically ill surgical patients with septic shock and could guide future fluid resuscitation strategies.
This is a single-center, randomized, open-label, controlled trial designed to evaluate the effect of targeted albumin replacement in adult patients with surgical septic shock. The study will be conducted in the Surgical Intensive Care Unit at Siriraj Hospital, Bangkok, Thailand.
Eligible patients are those aged 18 years or older admitted with surgical septic shock, defined as suspected or proven surgical infection requiring an operation or surgical intervention within 48 hours, and persisting shock despite adequate initial fluid resuscitation. After informed consent, participants will be randomized in a 1:1 ratio, using block randomization, to one of two groups:
Control group: Standard sepsis management according to international guidelines, including source control, broad-spectrum antibiotics, intravenous crystalloids, vasopressors, and other adjunctive therapies as required.
Intervention group: Standard care plus intravenous 20% human albumin solution, given for up to 72 hours, with dosing guided by serum albumin levels to maintain concentrations above 3.5 g/dL.
The primary endpoint is 28-day all-cause mortality. Secondary endpoints include length of ICU and hospital stay, ventilator-free days, vasopressor-free days, 7-day cumulative fluid balance, acute kidney injury requiring renal replacement therapy, recovery of gastrointestinal function, and adverse reactions.
The planned sample size is 304 patients (152 per arm), which provides 80% power to detect a relative risk reduction of 40% in 28-day mortality (from 35% to 20%) with two-sided alpha of 0.05, accounting for 10% attrition.
Data will be analyzed primarily on an intention-to-treat basis. Interim analysis is planned after 50% enrollment to assess safety and efficacy. Both frequentist and Bayesian approaches will be applied, including logistic regression to adjust for baseline imbalances if needed.
This trial will provide evidence on whether maintaining serum albumin above 3.5 g/dL with human albumin infusion improves survival and clinical outcomes in critically ill patients with surgical septic shock.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
This study's planned enrollment of 304 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →Mahidol University is the lead sponsor of 750 studies on the registry; 123 are open to participants now.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.
Other: Standard Care (in control arm)
Patients in this group will receive standard sepsis management as above, plus intravenous 20% human albumin solution. On admission, 50 mL of 20% albumin will be infused over 2 hours, followed by additional doses for up to 72 hours, titrated according to daily serum albumin levels. The target is to maintain serum albumin \>3.5 g/dL: 1 vial every 12 hours if 2.5-3.4 g/dL, or every 6 hours if \<2.5 g/dL. Infusion will be withheld in the presence of fluid overload, pulmonary edema, or severe hypernatremia.
Drug: Human Albumin 20% Solution · Other: Standard Care (in control arm)
Intravenous 20% human albumin solution (50 mL per vial). In the experimental arm, patients receive 50 mL over 2 hours on admission, followed by additional doses for up to 72 hours, titrated to maintain serum albumin \>3.5 g/dL. If albumin is 2.5-3.4 g/dL, 1 vial every 12 hours is given; if \<2.5 g/dL, 1 vial every 6 hours is given. Infusion is withheld if there is fluid overload, pulmonary edema, or severe hypernatremia.
Patients in this group will receive standard sepsis management according to international guidelines. This includes source control, intravenous broad-spectrum antibiotics, balanced crystalloids, vasopressors, and adjunctive therapies (e.g., corticosteroids, thiamine, ventilatory and renal support) as clinically indicated. Albumin may be given if separate indications arise (e.g., perioperative use, severe hypoalbuminemia \<2.5 g/dL with capillary leakage), at the discretion of the treating physician.
28-Day All-Cause Mortality
Mortality from any cause within 28 days of ICU admission, assessed by review of hospital records and/or telephone follow-up if the patient is discharged before Day 28.
Time frame: 28 days after randomization
ICU Length of Stay
Number of days from ICU admission to ICU discharge. For participants who die in the ICU, length of stay will be recorded up to the date of death.
Time frame: From ICU admission until ICU discharge or death in the ICU, assessed for up to 90 days.
Hospital Length of Stay
Number of days from hospital admission to hospital discharge. For participants who die in the hospital, length of stay will be recorded up to the date of death.
Time frame: From hospital admission until hospital discharge or in-hospital death, assessed for up to 90 days.
Vasopressor-Free Days
Number of days alive and without vasopressor therapy during the first 28 days. Patients who die before Day 28 will be assigned zero vasopressor-free days.
Time frame: 28 days after randomization
7-Day Cumulative Fluid Balance
Net fluid balance (total fluid input minus total output) recorded daily and summed across the first 7 days of ICU stay.
Time frame: First 7 days after randomization
Acute Kidney Injury Requiring Renal Replacement Therapy
Incidence of renal replacement therapy initiation for acute kidney injury, determined from ICU and hospital records.
Time frame: Up to 28 days after randomization
Adverse Reactions
Incidence of adverse reactions related to albumin infusion, including allergic or anaphylactic reactions, pulmonary edema, or electrolyte disturbances.
Time frame: Up to 28 days after randomization
Plan to share: No — Individual participant data (IPD) will not be shared because of institutional policies at Siriraj Hospital that restrict the transfer of identifiable patient-level data outside the institution. Only aggregate, de-identified data will be reported in publications and presentations. Researchers interested in collaboration may contact the study investigators to discuss potential data analyses consistent with local regulations.
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2029, 48 months later.
Of 45 non-industry phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's planned 48 months is above that.
Counting every sponsor, half of 46 studies reached it within 42 months; a quarter within 16 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumins human